These findings suggest that metformin mono-therapy may be harmful due to exacerbation of AD-type neurodegeneration [325], whereas the combined use of insulin and hypoglycemic drugs may benefit elderly patients in the early stages of AD by significantly improving cognitive performance and slowing the rate of neurodegeneration. The gene discussed is INS; the disease is Alzheimer disease.